I'm surprised they didn't release it as a NPS on ASX or at least...

First 2289 Last

Share
Profile

Follow
Akki

35,746 Posts.

554

19/10/20

14:43

Post #: 48204716
Share

Originally posted by samfiodiving ↑

Chaya good to see someone is buying up, the thing is mate, what a great report that is, yet if it wasn't for @Baremoney most of us here would be none the wiser that the report even existed

I have been onto the ANP web site no mention of it in investor relations under reports or any heading for that matter WHY

As Akki said they most probably paid for the report so why not get it out there

This is what i keep banging on about

YES they are all over the SCIENCE

But just as they are all over the Science they are grossly missing the mark @market

What is the point of drawing up such a brilliant report if know one knows it exists even shareholders that are always hungry for info didnt know

On a side note perhaps @ANPto2Dollars could throw some light on this but i searched last night under the google US search engine Antisense therapeutics and very little came up under the US search perhaps being as i say the concentration is going to be in the US perhaps they could look at lifting the profile in the US search engine

Expand

I'm surprised they didn't release it as a NPS on ASX or at least have up on the website.

They definitely paid it for it and CCR &/or analyst have no equity in ANP.

Wasn't just a random report though - and with access to management to prepare the report most of the details on timelines, expected trial structure etc would be straight from the horses mouth.

ANP Price at posting: 13.5¢ Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Good habits matters when it comes to finances

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

There are more pages in this discussion • 3,617 more messages in this thread...

First 2289 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.0¢		Change 0.000(0.00%)		Mkt cap ! $72.12M

Open	High	Low	Value	Volume
8.3¢	8.4¢	8.0¢	$99.06K	1.226M

Buyers (Bids)

No.	Vol.	Price($)
1	3500	7.8¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	40625	1

View Market Depth

No.	Vol.	Price($)
1	3500	0.078
1	10000	0.077
1	180000	0.076
4	186800	0.075
3	180866	0.074

Price($)	Vol.	No.
0.080	40625	1
0.084	120000	1
0.085	363000	2
0.086	480000	3
0.087	400000	1

Last trade - 16.10pm 19/08/2024 (20 minute delay)

PER (ASX) Chart

I'm surprised they didn't release it as a NPS on ASX or at least...

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Fourfold skarn increase points the way to viable garnet project, says Pure

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Good habits matters when it comes to finances

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'm surprised they didn't release it as a NPS on ASX or at least...

Top Stories

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Fourfold skarn increase points the way to viable garnet project, says Pure

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Good habits matters when it comes to finances

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News